Depemokimab, a twice-yearly anti-IL-5 biologic, significantly reduces nasal polyp score and obstruction in CRSwNP patients.
Background
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating type 2 inflammatory disease characterized by persistent inflammation and polyp formation, often requiring systemic glucocorticoids (SGCs) with their associated side effects. A key driver of this inflammation is interleukin-5 (IL-5), which promotes eosinophil survival and activation. While anti-IL-5 monoclonal antibodies exist, current options often require more frequent dosing. There is a clear need for therapies that offer sustained suppression of type 2 inflammation with improved convenience and adherence.
Study Design
This narrative review summarized the molecular profile, pharmacokinetics, pharmacodynamics, and clinical efficacy and safety of depemokimab, a novel anti-IL-5 biologic, from recently published Phase 3 clinical trials. Specifically, it focused on the ANCHOR-1 and ANCHOR-2 trials, which enrolled 528 severe adult CRSwNP patients. In these trials, patients received depemokimab 100 mg via subcutaneous (SC) injection twice-yearly, compared to a placebo arm. Primary endpoints included changes in total endoscopic nasal polyp score and nasal obstruction verbal response scale at week 52.
Results
Depemokimab demonstrated significant clinical efficacy and a favorable safety profile in severe adult CRSwNP patients. In the ANCHOR-1 and ANCHOR-2 Phase 3 trials, depemokimab achieved a mean change (Δ) in total endoscopic nasal polyp score of -0.70 (p < .001) at week 52 compared to placebo.
Nasal obstruction, a key symptom, also significantly improved, with a Δ nasal obstruction verbal response scale of -0.24 (p = .003) at week 52. The unique pharmacodynamic features of depemokimab, including its enhanced binding affinity and extended terminal elimination half-life of 6-8 weeks, enabled sustained suppression of type 2 inflammation. This led to durable eosinophil suppression, with a safety profile comparable to placebo, indicating good tolerability for twice-yearly 100 mg dosing.
Key Findings
- Depemokimab achieved a Δ total endoscopic nasal polyp score of -0.70 (p < .001) at week 52.
- Nasal obstruction verbal response scale improved by Δ -0.24 (p = .003) at week 52.
- Twice-yearly 100 mg subcutaneous dosing provides durable eosinophil suppression.
- Depemokimab's safety profile was comparable to placebo in Phase 3 trials.
- Extended half-life of 6-8 weeks enables twice-yearly administration.
Why It Matters
This review highlights a significant advancement for individuals suffering from CRSwNP, offering a highly convenient twice-yearly dosing regimen for an anti-IL-5 biologic. The extended dosing interval of depemokimab could dramatically improve patient adherence and quality of life, reducing the burden of frequent injections associated with other biologics. For clinicians, this presents a new, less frequent treatment option that maintains efficacy and safety. While the current data is from a narrative review of Phase 3 trials, the prospect of a twice-yearly protocol for a chronic condition like CRSwNP is a major step towards more patient-friendly and effective management strategies, potentially reducing reliance on systemic steroids.
depemokimab
crswnp
nasal-polyps
il-5-inhibitor
type-2-inflammation
monoclonal-antibody